Literature DB >> 10666836

13C-methacetin breath test: isotope-selective nondispersive infrared spectrometry in comparison to isotope ratio mass spectrometry in volunteers and patients with liver cirrhosis.

R J Adamek1, O Goetze, C Boedeker, B Pfaffenbach, A Luypaerts, B Geypens.   

Abstract

The 13C-methacetin breath test (MBT) has been proposed for the noninvasive evaluation of the hepatic mixed function oxidase activity. Up to now, stable isotope analysis of carbon dioxide of the MBT has been carried out with isotope ratio mass spectrometry (IRMS). The aim of the present study was to test a recently developed isotope-selective nondispersive infrared spectrometer (NDIRS) in comparison to IRMS in healthy volunteers and patients with liver cirrhosis. Ten healthy volunteers (range 22 to 76 years) and ten patients with histologically proven liver cirrhosis (range 47 to 71 years; Child Pugh score A = 5, B = 3, C = 2) were studied. After an overnight fast each subject received 2 mg/kg BW of 13C-methacetin dissolved in 100 ml of tea. Breath samples were obtained before substrate administration and after 5, 10, 15, 20, 30, 40, 50, 60, 80, 100, 120, 150, 180 min. The 13C/12C-ratio was analyzed in each breath sample both by NDIRS (IRIS, Wagner Analysen Technik, Worpswede, Germany) and CF-IRMS (ABCA, Europa Scientific, Crewe, UK). Results were expressed as delta over baseline (DOB [/1000]) and as cumulative percentage doses of 13C recovered (cPDR [%]) at each time interval. Correlations between IRMS and NDIRS were tested by linear regression correlation. For measuring agreement an Altman-Bland-plot was performed. Applying correlation analysis a linear correlation was found (DOB: y = 1.068 +/- 0.0012.x + 2.088 +/- 0.2126, r = 0.98, p < 0.0001; cPDR: y = 1.148 +/- 0.0109.x + 0.569 +/- 0.172; r = 0.99, p < 0.0001). For DOB the mean difference (d) was 2.9/1000 and the standard deviation (SD) of the difference was 2.7/1000. The limits of agreement (d +/- SD) were -2.5/1000 and 8.3/1000. The comparison of DOB- and cPDR-values by NDIRS and IRMS shows a high linear correlation. However, the distance of the limits of agreement is wide. Consequently, the validity of the MBT could be influenced which could make MBT by NDIRS unprecise for exact evaluation of hepatocellular dysfunction. Further studies are necessary to determine sensitivity and specifity of the MBT with NDIRS in larger study populations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10666836

Source DB:  PubMed          Journal:  Z Gastroenterol        ISSN: 0044-2771            Impact factor:   2.000


  5 in total

1.  Prospective Assessment of Liver Function by an Enzymatic Liver Function Test to Estimate Short-Term Survival in Patients with Liver Cirrhosis.

Authors:  Maximilian Jara; Tomasz Dziodzio; Maciej Malinowski; Katja Lüttgert; Radoslav Nikolov; Paul Viktor Ritschl; Robert Öllinger; Johann Pratschke; Martin Stockmann
Journal:  Dig Dis Sci       Date:  2018-11-07       Impact factor: 3.199

2.  Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.

Authors:  Gadi Lalazar; Tomer Adar; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2009-02-28       Impact factor: 5.742

3.  Diagnostic value of the C methacetin breath test in various stages of chronic liver disease.

Authors:  Hamizah Razlan; Nurhayaty Muhamad Marzuki; Mei-Ling Sharon Tai; Azhar-Shah Shamsul; Tze-Zen Ong; Sanjiv Mahadeva
Journal:  Gastroenterol Res Pract       Date:  2011-06-07       Impact factor: 2.260

4.  Interpretation of non-invasive breath tests using (13)C-labeled substrates--a preliminary report with (13)C-methacetin.

Authors:  J F Lock; P Taheri; S Bauer; H-G Holzhütter; M Malinowski; P Neuhaus; M Stockmann
Journal:  Eur J Med Res       Date:  2009       Impact factor: 2.175

5.  Gastrointestinal Dysfunction in Patients with Duchenne Muscular Dystrophy.

Authors:  Christian M Lo Cascio; Oliver Goetze; Tsogyal D Latshang; Sena Bluemel; Thomas Frauenfelder; Konrad E Bloch
Journal:  PLoS One       Date:  2016-10-13       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.